Information Provided By:
Fly News Breaks for February 18, 2020
Feb 18, 2020 | 16:12 EDT
Stifel analyst Paul Matteis initiated coverage of Denali Therapeutics with a Hold rating and $26 price target. While he likes the biological foundation of Denali's lead programs in Parkinson's, ALS/AD, and Hunter Syndrome he thinks the valuation near $3B diluted already ascribes a good deal of credit to the potential of the company's portfolio.
News For DNLI From the Last 2 Days
There are no results for your query DNLI